Glaukos' iDose TR for Glaucoma Hits the Market

Glaukos Corporation's iDose TR, using Celanese's VitalDose EVA (Ethylene Vinyl Acetate), to provide sustained drug release for the treatment of glaucoma has officially entered the commercial market.

Having received FDA approval in December, iDose TR represents a notable departure from traditional treatment approaches. It stands as the first prostaglandin analog intracameral implant intended for reducing intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma.

This novel procedure, approved for one administration per eye, ensures continuous delivery of therapeutic levels of a proprietary formulation of travoprost within the eye for extended periods. This approach aims to mitigate issues of patient non-compliance and chronic side effects commonly associated with topical glaucoma medications.

Glaucoma is a progressive eye condition characterized by damage to the optic nerve, typically caused by increased pressure within the eye. This heightened intraocular pressure can result from a buildup of fluid that fails to drain properly. Glaucoma often develops gradually and without noticeable symptoms, earning it the moniker "the silent thief of sight." If left untreated, it can lead to irreversible vision loss and blindness.

Glaukos has established a wholesale acquisition cost of $13,950 per dose (or implant) for iDose TR, underscoring its potential value in enhancing glaucoma management.

VitalDose EVA, utilized in iDose TR, plays a critical role in creating a nanoporous membrane for travoprost delivery. This platform offers versatility, enabling the formulation of various delivery mechanisms tailored to meet the specific requirements of different medical conditions.

Commenting on the launch, Cyonna Holmes, Global Business Strategy Leader for Ophthalmology and RNA at Celanese, emphasized the pressing need for innovative therapies in ophthalmology to address non-compliance and alleviate treatment burden for patients. Holmes stated, "A clear unmet need exists in ophthalmology for therapies that address non-compliance and reduce the treatment burden for patients. Our team is excited to support Glaukos as they transform the landscape of glaucoma treatment for millions of patients."